Physician profile
Andrew Spitzer
NPI 1619945581
$738,071.28
in general payments reported to CMS, 2019-2025
13 companies · $72K in 2025
The $72K reported for 2025 was more than what 96% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151K · 2020: $76K · 2021: $106K · 2022: $129K · 2023: $121K · 2024: $84K · 2025: $72K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $183K · Honoraria: $57K · Travel and Lodging: $26K · Food and Beverage: $4,282 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,144 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $183,283.14 |
| Honoraria | $56,987.50 |
| Travel and Lodging | $26,068.57 |
| Food and Beverage | $4,282.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,143.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $250,784.61 | 2021-2025 | Zilretta, Exparel, Iovera |
| Pacira Therapeutics, INC. | $245,323.84 | 2019-2021 | |
| Medical Device Business Services, INC. | $184,461.25 | 2019-2025 | Attune, Sigma, Endurance |
| Zimmer Biomet Holdings, INC. | $39,491.46 | 2022-2025 | Arcos, Persona |
| Sanofi-Aventis U.S. LLC | $10,153.00 | 2019 | |
| Averitas Pharma INC. | $3,044.67 | 2024 | |
| Synthes Gmbh | $2,459.17 | 2024 | |
| Depuy Synthes Sales INC. | $768.35 | 2019-2025 | Attune |
| Depuy Synthes Products, INC. | $675.00 | 2023 | Attune, Sigma |
| Brainlab, INC. | $381.73 | 2019 | |
| Smith+Nephew, INC. | $309.34 | 2019 | |
| Stryker Corporation | $218.86 | 2025 | Mako |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Spitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.